nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0792	0.175	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0395	0.0872	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0377	0.0831	CbGbCtD
Nilotinib—ABCG2—Methotrexate—ankylosing spondylitis	0.0318	0.0701	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—ankylosing spondylitis	0.0278	0.0613	CbGbCtD
Nilotinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0245	0.054	CbGbCtD
Nilotinib—ABCB1—Prednisolone—ankylosing spondylitis	0.0242	0.0533	CbGbCtD
Nilotinib—ABCB1—Prednisone—ankylosing spondylitis	0.0228	0.0504	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0226	0.0498	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0211	0.0464	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0171	0.0377	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0147	0.0324	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0147	0.0324	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0145	0.0319	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0143	0.0314	CbGbCtD
Nilotinib—CYP3A4—Prednisone—ankylosing spondylitis	0.0137	0.0302	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0134	0.0296	CbGbCtD
Nilotinib—ABCB1—Methotrexate—ankylosing spondylitis	0.0115	0.0253	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00854	0.0188	CbGbCtD
Nilotinib—MAPK8—cartilage tissue—ankylosing spondylitis	0.00738	0.29	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—ankylosing spondylitis	0.00143	0.174	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—ankylosing spondylitis	0.0014	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—ankylosing spondylitis	0.0014	0.172	CbGdCrCtD
Nilotinib—CDC42BPB—tendon—ankylosing spondylitis	0.0014	0.0547	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—ankylosing spondylitis	0.00137	0.168	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisone—ankylosing spondylitis	0.0013	0.159	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisolone—ankylosing spondylitis	0.00127	0.155	CbGdCrCtD
Nilotinib—MAPK8—tendon—ankylosing spondylitis	0.00126	0.0495	CbGeAlD
Nilotinib—MAP4K1—tendon—ankylosing spondylitis	0.00115	0.045	CbGeAlD
Nilotinib—BRAF—tendon—ankylosing spondylitis	0.00105	0.0412	CbGeAlD
Nilotinib—HCK—tendon—ankylosing spondylitis	0.000957	0.0375	CbGeAlD
Nilotinib—ABL2—tendon—ankylosing spondylitis	0.000951	0.0373	CbGeAlD
Nilotinib—EPHA4—tendon—ankylosing spondylitis	0.00087	0.0341	CbGeAlD
Nilotinib—CA3—tendon—ankylosing spondylitis	0.000859	0.0337	CbGeAlD
Nilotinib—CA9—tendon—ankylosing spondylitis	0.000822	0.0322	CbGeAlD
Nilotinib—MAPK14—tendon—ankylosing spondylitis	0.000802	0.0314	CbGeAlD
Nilotinib—FGR—tendon—ankylosing spondylitis	0.000799	0.0313	CbGeAlD
Nilotinib—CA14—tendon—ankylosing spondylitis	0.00078	0.0306	CbGeAlD
Nilotinib—EPHB4—tendon—ankylosing spondylitis	0.00076	0.0298	CbGeAlD
Nilotinib—EPHA2—tendon—ankylosing spondylitis	0.000746	0.0292	CbGeAlD
Nilotinib—TEK—tendon—ankylosing spondylitis	0.000727	0.0285	CbGeAlD
Nilotinib—EPHB6—tendon—ankylosing spondylitis	0.000695	0.0273	CbGeAlD
Nilotinib—PDGFRA—tendon—ankylosing spondylitis	0.000659	0.0258	CbGeAlD
Nilotinib—MAP2K5—tendon—ankylosing spondylitis	0.000595	0.0233	CbGeAlD
Nilotinib—CSF1R—tendon—ankylosing spondylitis	0.00058	0.0228	CbGeAlD
Nilotinib—PDGFRB—tendon—ankylosing spondylitis	0.000515	0.0202	CbGeAlD
Nilotinib—ABL1—tendon—ankylosing spondylitis	0.000459	0.018	CbGeAlD
Nilotinib—CA4—tendon—ankylosing spondylitis	0.000377	0.0148	CbGeAlD
Nilotinib—CA2—tendon—ankylosing spondylitis	0.000312	0.0122	CbGeAlD
Nilotinib—Syncope—Betamethasone—ankylosing spondylitis	0.000257	0.000763	CcSEcCtD
Nilotinib—Syncope—Dexamethasone—ankylosing spondylitis	0.000257	0.000763	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000256	0.00076	CcSEcCtD
Nilotinib—Infection—Triamcinolone—ankylosing spondylitis	0.000256	0.00076	CcSEcCtD
Nilotinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000255	0.000758	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—ankylosing spondylitis	0.000254	0.000755	CcSEcCtD
Nilotinib—Shock—Triamcinolone—ankylosing spondylitis	0.000253	0.000753	CcSEcCtD
Nilotinib—Insomnia—Prednisolone—ankylosing spondylitis	0.000253	0.000753	CcSEcCtD
Nilotinib—Alopecia—Prednisone—ankylosing spondylitis	0.000253	0.000752	CcSEcCtD
Nilotinib—Shock—Methylprednisolone—ankylosing spondylitis	0.000253	0.000751	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000252	0.000749	CcSEcCtD
Nilotinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000252	0.000749	CcSEcCtD
Nilotinib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000252	0.000748	CcSEcCtD
Nilotinib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000252	0.000748	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000251	0.000747	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000251	0.000747	CcSEcCtD
Nilotinib—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000251	0.000747	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—ankylosing spondylitis	0.000251	0.000746	CcSEcCtD
Nilotinib—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000251	0.000745	CcSEcCtD
Nilotinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00025	0.000742	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000249	0.000741	CcSEcCtD
Nilotinib—Erythema—Prednisone—ankylosing spondylitis	0.000249	0.000741	CcSEcCtD
Nilotinib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000249	0.00074	CcSEcCtD
Nilotinib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000248	0.000738	CcSEcCtD
Nilotinib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000247	0.000734	CcSEcCtD
Nilotinib—Hypertension—Betamethasone—ankylosing spondylitis	0.000247	0.000734	CcSEcCtD
Nilotinib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000244	0.000724	CcSEcCtD
Nilotinib—Myalgia—Betamethasone—ankylosing spondylitis	0.000244	0.000724	CcSEcCtD
Nilotinib—Anxiety—Dexamethasone—ankylosing spondylitis	0.000243	0.000722	CcSEcCtD
Nilotinib—Anxiety—Betamethasone—ankylosing spondylitis	0.000243	0.000722	CcSEcCtD
Nilotinib—Discomfort—Dexamethasone—ankylosing spondylitis	0.000241	0.000716	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—ankylosing spondylitis	0.000241	0.000716	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000241	0.000715	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00024	0.000713	CcSEcCtD
Nilotinib—Pain—Prednisolone—ankylosing spondylitis	0.000239	0.000711	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000239	0.000711	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—ankylosing spondylitis	0.000239	0.000711	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000238	0.000706	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000236	0.000702	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—ankylosing spondylitis	0.000235	0.000698	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000235	0.000697	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000235	0.000697	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000234	0.000696	CcSEcCtD
Nilotinib—Oedema—Betamethasone—ankylosing spondylitis	0.000234	0.000694	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000234	0.000694	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000233	0.000692	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000232	0.00069	CcSEcCtD
Nilotinib—Infection—Dexamethasone—ankylosing spondylitis	0.000232	0.00069	CcSEcCtD
Nilotinib—Infection—Betamethasone—ankylosing spondylitis	0.000232	0.00069	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000231	0.000687	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000231	0.000687	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000231	0.000686	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000231	0.000686	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—ankylosing spondylitis	0.000231	0.000685	CcSEcCtD
Nilotinib—Anaemia—Prednisone—ankylosing spondylitis	0.00023	0.000685	CcSEcCtD
Nilotinib—Shock—Betamethasone—ankylosing spondylitis	0.00023	0.000683	CcSEcCtD
Nilotinib—Shock—Dexamethasone—ankylosing spondylitis	0.00023	0.000683	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00023	0.000682	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000229	0.000681	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000229	0.000681	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000229	0.00068	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000229	0.00068	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—ankylosing spondylitis	0.000228	0.000678	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000228	0.000678	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000227	0.000674	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000226	0.000672	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000226	0.000672	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000226	0.000671	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000226	0.000671	CcSEcCtD
Nilotinib—Malaise—Prednisone—ankylosing spondylitis	0.000225	0.000668	CcSEcCtD
Nilotinib—Vertigo—Prednisone—ankylosing spondylitis	0.000224	0.000666	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000224	0.000665	CcSEcCtD
Nilotinib—Syncope—Prednisone—ankylosing spondylitis	0.000224	0.000664	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—ankylosing spondylitis	0.000223	0.000663	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—ankylosing spondylitis	0.000223	0.000662	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000223	0.000662	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—ankylosing spondylitis	0.000222	0.000661	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000222	0.00066	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000222	0.00066	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000221	0.000658	CcSEcCtD
Nilotinib—Pain—Triamcinolone—ankylosing spondylitis	0.00022	0.000654	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000219	0.000651	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000218	0.000649	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—ankylosing spondylitis	0.000218	0.000649	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000217	0.000645	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000216	0.000642	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000216	0.000641	CcSEcCtD
Nilotinib—Hypertension—Prednisone—ankylosing spondylitis	0.000215	0.00064	CcSEcCtD
Nilotinib—Chills—Methotrexate—ankylosing spondylitis	0.000215	0.000638	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000213	0.000633	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000213	0.000633	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—ankylosing spondylitis	0.000212	0.000631	CcSEcCtD
Nilotinib—Myalgia—Prednisone—ankylosing spondylitis	0.000212	0.000631	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000212	0.000631	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000212	0.000629	CcSEcCtD
Nilotinib—Anxiety—Prednisone—ankylosing spondylitis	0.000211	0.000628	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—ankylosing spondylitis	0.000211	0.000628	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000211	0.000628	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—ankylosing spondylitis	0.000211	0.000628	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000211	0.000626	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00021	0.000624	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00021	0.000623	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00021	0.000623	CcSEcCtD
Nilotinib—Discomfort—Prednisone—ankylosing spondylitis	0.00021	0.000623	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—ankylosing spondylitis	0.00021	0.000623	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000208	0.000619	CcSEcCtD
Nilotinib—Erythema—Methotrexate—ankylosing spondylitis	0.000208	0.000619	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000206	0.000613	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000206	0.000611	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000206	0.000611	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—ankylosing spondylitis	0.000205	0.000608	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000204	0.000606	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000204	0.000606	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000204	0.000605	CcSEcCtD
Nilotinib—Oedema—Prednisone—ankylosing spondylitis	0.000203	0.000605	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000203	0.000603	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000203	0.000603	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000203	0.000603	CcSEcCtD
Nilotinib—Infection—Prednisone—ankylosing spondylitis	0.000202	0.000601	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000202	0.000599	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000202	0.000599	CcSEcCtD
Nilotinib—Back pain—Methotrexate—ankylosing spondylitis	0.000202	0.000599	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000201	0.000599	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000201	0.000599	CcSEcCtD
Nilotinib—Shock—Prednisone—ankylosing spondylitis	0.0002	0.000595	CcSEcCtD
Nilotinib—Pain—Dexamethasone—ankylosing spondylitis	0.0002	0.000594	CcSEcCtD
Nilotinib—Pain—Betamethasone—ankylosing spondylitis	0.0002	0.000594	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.0002	0.000593	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—ankylosing spondylitis	0.000199	0.00059	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000198	0.000587	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000197	0.000584	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000196	0.000583	CcSEcCtD
Nilotinib—Anorexia—Prednisone—ankylosing spondylitis	0.000194	0.000576	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000193	0.000574	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—ankylosing spondylitis	0.000193	0.000572	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000193	0.000572	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000193	0.000572	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000191	0.000568	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000191	0.000568	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00019	0.000564	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000189	0.000562	CcSEcCtD
Nilotinib—Malaise—Methotrexate—ankylosing spondylitis	0.000188	0.000558	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—ankylosing spondylitis	0.000187	0.000556	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000186	0.000554	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—ankylosing spondylitis	0.000186	0.000552	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—ankylosing spondylitis	0.000186	0.000552	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000185	0.000551	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000185	0.00055	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000185	0.000549	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000185	0.000549	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000185	0.000549	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000185	0.000549	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000185	0.000549	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000184	0.000548	CcSEcCtD
Nilotinib—Insomnia—Prednisone—ankylosing spondylitis	0.000184	0.000547	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000183	0.000543	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000182	0.000541	CcSEcCtD
Nilotinib—Cough—Methotrexate—ankylosing spondylitis	0.000182	0.00054	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000182	0.00054	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000179	0.000532	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—ankylosing spondylitis	0.000177	0.000527	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000177	0.000527	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—ankylosing spondylitis	0.000177	0.000527	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000177	0.000526	CcSEcCtD
Nilotinib—Rash—Prednisolone—ankylosing spondylitis	0.000177	0.000525	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000176	0.000524	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000176	0.000523	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000176	0.000522	CcSEcCtD
Nilotinib—Fatigue—Prednisone—ankylosing spondylitis	0.000175	0.000521	CcSEcCtD
Nilotinib—Headache—Prednisolone—ankylosing spondylitis	0.000175	0.000521	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—ankylosing spondylitis	0.000175	0.000521	CcSEcCtD
Nilotinib—Constipation—Prednisone—ankylosing spondylitis	0.000174	0.000517	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—ankylosing spondylitis	0.000171	0.000509	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.00017	0.000506	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00017	0.000505	CcSEcCtD
Nilotinib—Infection—Methotrexate—ankylosing spondylitis	0.000169	0.000502	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000168	0.000498	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000168	0.000498	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000168	0.000498	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000167	0.000496	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000166	0.000495	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000166	0.000494	CcSEcCtD
Nilotinib—Nausea—Prednisolone—ankylosing spondylitis	0.000166	0.000494	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000165	0.000491	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000165	0.000491	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000165	0.000491	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000164	0.000488	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000164	0.000486	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000163	0.000485	CcSEcCtD
Nilotinib—Rash—Triamcinolone—ankylosing spondylitis	0.000162	0.000482	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000162	0.000482	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—ankylosing spondylitis	0.000162	0.000482	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000162	0.000481	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000162	0.000481	CcSEcCtD
Nilotinib—Urticaria—Prednisone—ankylosing spondylitis	0.000162	0.00048	CcSEcCtD
Nilotinib—Headache—Triamcinolone—ankylosing spondylitis	0.000161	0.000479	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000161	0.000478	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000161	0.000478	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000161	0.000478	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00016	0.000475	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00016	0.000475	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—ankylosing spondylitis	0.000159	0.000472	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000155	0.00046	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000154	0.000459	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000154	0.000459	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—ankylosing spondylitis	0.000154	0.000457	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000153	0.000454	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000153	0.000454	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000153	0.000453	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000152	0.00045	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00015	0.000445	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.00015	0.000445	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000149	0.000441	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000149	0.000441	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000148	0.000439	CcSEcCtD
Nilotinib—Rash—Dexamethasone—ankylosing spondylitis	0.000147	0.000438	CcSEcCtD
Nilotinib—Rash—Betamethasone—ankylosing spondylitis	0.000147	0.000438	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000147	0.000437	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000147	0.000437	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000147	0.000436	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000147	0.000436	CcSEcCtD
Nilotinib—Headache—Dexamethasone—ankylosing spondylitis	0.000146	0.000435	CcSEcCtD
Nilotinib—Headache—Betamethasone—ankylosing spondylitis	0.000146	0.000435	CcSEcCtD
Nilotinib—Asthenia—Prednisone—ankylosing spondylitis	0.000146	0.000434	CcSEcCtD
Nilotinib—Pain—Methotrexate—ankylosing spondylitis	0.000145	0.000432	CcSEcCtD
Nilotinib—Pruritus—Prednisone—ankylosing spondylitis	0.000144	0.000428	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.00014	0.000416	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000139	0.000414	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000139	0.000413	CcSEcCtD
Nilotinib—Nausea—Betamethasone—ankylosing spondylitis	0.000139	0.000412	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000139	0.000412	CcSEcCtD
Nilotinib—ABL1—Immune System—ERAP1—ankylosing spondylitis	0.000136	0.000771	CbGpPWpGaD
Nilotinib—MAP2K5—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000136	0.000769	CbGpPWpGaD
Nilotinib—Urticaria—Methotrexate—ankylosing spondylitis	0.000135	0.000401	CcSEcCtD
Nilotinib—LYN—Innate Immune System—HLA-C—ankylosing spondylitis	0.000135	0.000764	CbGpPWpGaD
Nilotinib—Dizziness—Prednisone—ankylosing spondylitis	0.000135	0.0004	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000134	0.000399	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000134	0.000399	CcSEcCtD
Nilotinib—ABL1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000134	0.000761	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000134	0.000761	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—HLA-B—ankylosing spondylitis	0.000133	0.000753	CbGpPWpGaD
Nilotinib—LCK—HIV Infection—HLA-A—ankylosing spondylitis	0.000133	0.000753	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—HLA-B—ankylosing spondylitis	0.000132	0.000751	CbGpPWpGaD
Nilotinib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000132	0.00075	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000132	0.00075	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000132	0.000747	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-C—ankylosing spondylitis	0.000131	0.000742	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-C—ankylosing spondylitis	0.000131	0.000742	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-C—ankylosing spondylitis	0.00013	0.00074	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—CRP—ankylosing spondylitis	0.00013	0.000735	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERAP1—ankylosing spondylitis	0.00013	0.000735	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000129	0.000734	CbGpPWpGaD
Nilotinib—Vomiting—Prednisone—ankylosing spondylitis	0.000129	0.000384	CcSEcCtD
Nilotinib—BRAF—Disease—B3GNT2—ankylosing spondylitis	0.000129	0.000732	CbGpPWpGaD
Nilotinib—CA9—Metabolism—B3GNT2—ankylosing spondylitis	0.000129	0.000732	CbGpPWpGaD
Nilotinib—MAPK8—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000129	0.00073	CbGpPWpGaD
Nilotinib—Rash—Prednisone—ankylosing spondylitis	0.000128	0.000381	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000128	0.000381	CcSEcCtD
Nilotinib—MAPK14—Innate Immune System—HLA-C—ankylosing spondylitis	0.000128	0.000724	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CARD9—ankylosing spondylitis	0.000128	0.000724	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000128	0.000723	CbGpPWpGaD
Nilotinib—Headache—Prednisone—ankylosing spondylitis	0.000127	0.000379	CcSEcCtD
Nilotinib—HCK—Immune System—IL1RN—ankylosing spondylitis	0.000125	0.000711	CbGpPWpGaD
Nilotinib—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000125	0.000372	CcSEcCtD
Nilotinib—LYN—Immune System—CARD9—ankylosing spondylitis	0.000125	0.000709	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CARD9—ankylosing spondylitis	0.000124	0.000705	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—TLR4—ankylosing spondylitis	0.000124	0.000705	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000123	0.000698	CbGpPWpGaD
Nilotinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000122	0.000363	CcSEcCtD
Nilotinib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000121	0.000686	CbGpPWpGaD
Nilotinib—Nausea—Prednisone—ankylosing spondylitis	0.000121	0.000359	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—ankylosing spondylitis	0.00012	0.000357	CcSEcCtD
Nilotinib—MAPK14—Immune System—CARD9—ankylosing spondylitis	0.000118	0.000672	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000118	0.00067	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000118	0.00067	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1R2—ankylosing spondylitis	0.000118	0.00067	CbGpPWpGaD
Nilotinib—KIT—Disease—B3GNT2—ankylosing spondylitis	0.000118	0.000666	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—CRP—ankylosing spondylitis	0.000117	0.000666	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—CRP—ankylosing spondylitis	0.000117	0.000664	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000116	0.000661	CbGpPWpGaD
Nilotinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000116	0.000346	CcSEcCtD
Nilotinib—EPHB3—Developmental Biology—TNF—ankylosing spondylitis	0.000114	0.000648	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1RN—ankylosing spondylitis	0.000114	0.000645	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1RN—ankylosing spondylitis	0.000114	0.000645	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1RN—ankylosing spondylitis	0.000113	0.000642	CbGpPWpGaD
Nilotinib—BRAF—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000113	0.000638	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—TLR4—ankylosing spondylitis	0.000113	0.000638	CbGpPWpGaD
Nilotinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000112	0.000334	CcSEcCtD
Nilotinib—FGR—Innate Immune System—TLR4—ankylosing spondylitis	0.000112	0.000636	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERAP1—ankylosing spondylitis	0.000112	0.000635	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000112	0.000634	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	0.000111	0.000631	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	0.00011	0.000626	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD79A—ankylosing spondylitis	0.00011	0.000625	CbGpPWpGaD
Nilotinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000108	0.000321	CcSEcCtD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000108	0.000612	CbGpPWpGaD
Nilotinib—Rash—Methotrexate—ankylosing spondylitis	0.000107	0.000319	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000107	0.000318	CcSEcCtD
Nilotinib—Headache—Methotrexate—ankylosing spondylitis	0.000107	0.000317	CcSEcCtD
Nilotinib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000106	0.000601	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—HLA-B—ankylosing spondylitis	0.000106	0.0006	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-C—ankylosing spondylitis	0.000104	0.000591	CbGpPWpGaD
Nilotinib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000102	0.000581	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—TNF—ankylosing spondylitis	0.000102	0.000577	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—TNF—ankylosing spondylitis	0.000102	0.000577	CbGpPWpGaD
Nilotinib—Nausea—Methotrexate—ankylosing spondylitis	0.000101	0.0003	CcSEcCtD
Nilotinib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000101	0.000572	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	0.0001	0.000568	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD79A—ankylosing spondylitis	9.98e-05	0.000566	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD79A—ankylosing spondylitis	9.98e-05	0.000566	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD79A—ankylosing spondylitis	9.95e-05	0.000564	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD79A—ankylosing spondylitis	9.87e-05	0.00056	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—TNF—ankylosing spondylitis	9.82e-05	0.000557	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—TNF—ankylosing spondylitis	9.71e-05	0.000551	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—TNF—ankylosing spondylitis	9.71e-05	0.000551	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	9.64e-05	0.000546	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	9.54e-05	0.000541	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	9.44e-05	0.000535	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—TNF—ankylosing spondylitis	9.4e-05	0.000533	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-C—ankylosing spondylitis	9.4e-05	0.000533	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—CRP—ankylosing spondylitis	9.36e-05	0.000531	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.17e-05	0.00052	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—TNF—ankylosing spondylitis	9.13e-05	0.000518	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	9.12e-05	0.000517	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1RN—ankylosing spondylitis	9.06e-05	0.000514	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	9.04e-05	0.000512	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL1A—ankylosing spondylitis	9.03e-05	0.000512	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD40LG—ankylosing spondylitis	8.98e-05	0.000509	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—TLR4—ankylosing spondylitis	8.97e-05	0.000509	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	8.9e-05	0.000505	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.75e-05	0.000496	CbGpPWpGaD
Nilotinib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	8.74e-05	0.000496	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.68e-05	0.000492	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	8.58e-05	0.000487	CbGpPWpGaD
Nilotinib—HCK—Immune System—HLA-B—ankylosing spondylitis	8.54e-05	0.000484	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.49e-05	0.000482	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CRP—ankylosing spondylitis	8.44e-05	0.000478	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.22e-05	0.000466	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1A—ankylosing spondylitis	8.18e-05	0.000464	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1A—ankylosing spondylitis	8.18e-05	0.000464	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1RN—ankylosing spondylitis	8.17e-05	0.000463	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1A—ankylosing spondylitis	8.15e-05	0.000462	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	8.14e-05	0.000462	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD40LG—ankylosing spondylitis	8.14e-05	0.000461	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD40LG—ankylosing spondylitis	8.14e-05	0.000461	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—TNF—ankylosing spondylitis	8.11e-05	0.00046	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD40LG—ankylosing spondylitis	8.11e-05	0.00046	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	8.09e-05	0.000459	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	8.09e-05	0.000459	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.05e-05	0.000456	CbGpPWpGaD
Nilotinib—LCK—Disease—B3GNT2—ankylosing spondylitis	8.04e-05	0.000456	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.04e-05	0.000456	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	8.02e-05	0.000455	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	7.99e-05	0.000453	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	7.97e-05	0.000452	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD79A—ankylosing spondylitis	7.95e-05	0.000451	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	7.93e-05	0.00045	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—TNF—ankylosing spondylitis	7.92e-05	0.000449	CbGpPWpGaD
Nilotinib—HCK—Immune System—HLA-A—ankylosing spondylitis	7.91e-05	0.000449	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PTGER4—ankylosing spondylitis	7.86e-05	0.000446	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-C—ankylosing spondylitis	7.85e-05	0.000445	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.82e-05	0.000443	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	7.81e-05	0.000443	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-B—ankylosing spondylitis	7.74e-05	0.000439	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-B—ankylosing spondylitis	7.74e-05	0.000439	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	7.73e-05	0.000438	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-B—ankylosing spondylitis	7.71e-05	0.000437	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—B3GNT2—ankylosing spondylitis	7.69e-05	0.000436	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.69e-05	0.000436	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	7.66e-05	0.000434	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.65e-05	0.000434	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HLA-B—ankylosing spondylitis	7.55e-05	0.000428	CbGpPWpGaD
Nilotinib—HCK—Immune System—CRP—ankylosing spondylitis	7.55e-05	0.000428	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	7.47e-05	0.000424	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-C—ankylosing spondylitis	7.44e-05	0.000422	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.32e-05	0.000415	CbGpPWpGaD
Nilotinib—HCK—Disease—HLA-A—ankylosing spondylitis	7.31e-05	0.000414	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.24e-05	0.000411	CbGpPWpGaD
Nilotinib—HCK—Immune System—TLR4—ankylosing spondylitis	7.24e-05	0.00041	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	7.19e-05	0.000408	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD79A—ankylosing spondylitis	7.17e-05	0.000407	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-A—ankylosing spondylitis	7.17e-05	0.000407	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-A—ankylosing spondylitis	7.17e-05	0.000407	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-A—ankylosing spondylitis	7.15e-05	0.000405	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.09e-05	0.000402	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CRP—ankylosing spondylitis	7.04e-05	0.000399	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	7.01e-05	0.000398	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	6.96e-05	0.000395	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	6.9e-05	0.000391	CbGpPWpGaD
Nilotinib—BLK—Immune System—CRP—ankylosing spondylitis	6.84e-05	0.000388	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CRP—ankylosing spondylitis	6.84e-05	0.000388	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1RN—ankylosing spondylitis	6.82e-05	0.000387	CbGpPWpGaD
Nilotinib—FGR—Immune System—CRP—ankylosing spondylitis	6.82e-05	0.000387	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	6.79e-05	0.000385	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	6.79e-05	0.000385	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	6.75e-05	0.000383	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	6.72e-05	0.000381	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	6.72e-05	0.000381	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CRP—ankylosing spondylitis	6.68e-05	0.000379	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.59e-05	0.000374	CbGpPWpGaD
Nilotinib—BLK—Immune System—TLR4—ankylosing spondylitis	6.56e-05	0.000372	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—TLR4—ankylosing spondylitis	6.56e-05	0.000372	CbGpPWpGaD
Nilotinib—FGR—Immune System—TLR4—ankylosing spondylitis	6.54e-05	0.000371	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	6.53e-05	0.00037	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	6.53e-05	0.00037	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1A—ankylosing spondylitis	6.52e-05	0.00037	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD40LG—ankylosing spondylitis	6.48e-05	0.000368	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1RN—ankylosing spondylitis	6.46e-05	0.000367	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-C—ankylosing spondylitis	6.43e-05	0.000365	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—TLR4—ankylosing spondylitis	6.4e-05	0.000363	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.27e-05	0.000356	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTGER4—ankylosing spondylitis	6.26e-05	0.000355	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTGER4—ankylosing spondylitis	6.2e-05	0.000352	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-B—ankylosing spondylitis	6.17e-05	0.00035	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	6.11e-05	0.000347	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD79A—ankylosing spondylitis	5.99e-05	0.000339	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD79A—ankylosing spondylitis	5.96e-05	0.000338	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1A—ankylosing spondylitis	5.88e-05	0.000333	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD40LG—ankylosing spondylitis	5.84e-05	0.000331	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.81e-05	0.00033	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	5.77e-05	0.000327	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-A—ankylosing spondylitis	5.71e-05	0.000324	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD79A—ankylosing spondylitis	5.67e-05	0.000322	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	5.64e-05	0.00032	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP3—ankylosing spondylitis	5.59e-05	0.000317	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1RN—ankylosing spondylitis	5.59e-05	0.000317	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	5.56e-05	0.000316	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-B—ankylosing spondylitis	5.56e-05	0.000315	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	5.54e-05	0.000314	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	5.53e-05	0.000314	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CRP—ankylosing spondylitis	5.45e-05	0.000309	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	5.34e-05	0.000303	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	5.32e-05	0.000302	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	5.26e-05	0.000298	CbGpPWpGaD
Nilotinib—BRAF—Disease—HLA-A—ankylosing spondylitis	5.22e-05	0.000296	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—TLR4—ankylosing spondylitis	5.22e-05	0.000296	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-A—ankylosing spondylitis	5.15e-05	0.000292	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	5.01e-05	0.000284	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	4.98e-05	0.000283	CbGpPWpGaD
Nilotinib—KIT—Immune System—CRP—ankylosing spondylitis	4.91e-05	0.000279	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1A—ankylosing spondylitis	4.91e-05	0.000278	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD79A—ankylosing spondylitis	4.91e-05	0.000278	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1A—ankylosing spondylitis	4.89e-05	0.000277	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—ankylosing spondylitis	4.88e-05	0.000277	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	4.88e-05	0.000276	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	4.86e-05	0.000275	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	4.81e-05	0.000273	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—ankylosing spondylitis	4.8e-05	0.000272	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—B3GNT2—ankylosing spondylitis	4.78e-05	0.000271	CbGpPWpGaD
Nilotinib—KIT—Disease—HLA-A—ankylosing spondylitis	4.76e-05	0.00027	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	4.74e-05	0.000269	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	4.71e-05	0.000267	CbGpPWpGaD
Nilotinib—KIT—Immune System—TLR4—ankylosing spondylitis	4.71e-05	0.000267	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1A—ankylosing spondylitis	4.65e-05	0.000264	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CRP—ankylosing spondylitis	4.65e-05	0.000264	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-B—ankylosing spondylitis	4.64e-05	0.000263	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—ankylosing spondylitis	4.63e-05	0.000262	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	4.62e-05	0.000262	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	4.5e-05	0.000255	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTGER4—ankylosing spondylitis	4.47e-05	0.000253	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	4.46e-05	0.000253	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP3—ankylosing spondylitis	4.46e-05	0.000253	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP3—ankylosing spondylitis	4.42e-05	0.00025	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-B—ankylosing spondylitis	4.4e-05	0.00025	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	4.39e-05	0.000249	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-A—ankylosing spondylitis	4.3e-05	0.000244	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	4.28e-05	0.000243	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CRP—ankylosing spondylitis	4.19e-05	0.000238	CbGpPWpGaD
Nilotinib—LYN—Immune System—CRP—ankylosing spondylitis	4.1e-05	0.000233	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CRP—ankylosing spondylitis	4.08e-05	0.000232	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-A—ankylosing spondylitis	4.08e-05	0.000231	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	4.06e-05	0.00023	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	4.05e-05	0.00023	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1A—ankylosing spondylitis	4.02e-05	0.000228	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	4.02e-05	0.000228	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	4.02e-05	0.000228	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—ankylosing spondylitis	4e-05	0.000227	CbGpPWpGaD
Nilotinib—LYN—Immune System—TLR4—ankylosing spondylitis	3.93e-05	0.000223	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TLR4—ankylosing spondylitis	3.92e-05	0.000222	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CRP—ankylosing spondylitis	3.89e-05	0.000221	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	3.86e-05	0.000219	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-B—ankylosing spondylitis	3.8e-05	0.000216	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	3.8e-05	0.000216	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TLR4—ankylosing spondylitis	3.73e-05	0.000211	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—ankylosing spondylitis	3.61e-05	0.000205	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	3.59e-05	0.000204	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.53e-05	0.0002	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-A—ankylosing spondylitis	3.53e-05	0.0002	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	3.43e-05	0.000194	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—ankylosing spondylitis	3.42e-05	0.000194	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—ankylosing spondylitis	3.36e-05	0.000191	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.36e-05	0.00019	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.32e-05	0.000189	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.32e-05	0.000188	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	3.3e-05	0.000187	CbGpPWpGaD
Nilotinib—LCK—Disease—HLA-A—ankylosing spondylitis	3.25e-05	0.000185	CbGpPWpGaD
Nilotinib—LCK—Immune System—TLR4—ankylosing spondylitis	3.22e-05	0.000183	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP3—ankylosing spondylitis	3.18e-05	0.00018	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	2.75e-05	0.000156	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.17e-05	0.000123	CbGpPWpGaD
